The utilization of hepatocytes for cellular gene therapy would be greatly added by the ability to culture and passage primary hepatocytes in vitro. A period of in vitro growth would allow introduction of critical genes and an analysis of their expression prior to the transplantation into the recipient. In addition, the identification of cell types with prolonged proliferative capacities, both in vitro and in vivo, will be essential to sustained correction which are important for hepatocyte cell proliferation in vitro. We will utilize our present protocol which gives survival for over two weeks and continued expression of liver specific functions as baseline conditions. Factors from a variety of sources will be tested for their ability to increase DNA synthesis or prolong survival. The second goal will be to use cellular transplantation as an assay system for cells capable of proliferation and hepatospecific gene expression in vivo. The general strategy for this goal will be to isolate cells from transgenic animals carrying the chloramphenicol acetyltransferase (CAT) gene as a marker. Various cell fractions from the liver and the pancreas marked by CAT will be reintroduced into a recipient animal by transplantation. The donor cells which repopulate the recipient liver will then be assessed for their proliferative capacity and their ability to express a variety of hepatic gene products. Isolation of, or enrich for, cells of the liver which have prolonged growth potential will greatly enhance the feasibility of cellular transplantation as a gene therapy modality.

Project Start
Project End
Budget Start
Budget End
Support Year
2
Fiscal Year
1992
Total Cost
Indirect Cost
Name
Baylor College of Medicine
Department
Type
DUNS #
074615394
City
Houston
State
TX
Country
United States
Zip Code
77030
Tarlow, Branden D; Pelz, Carl; Naugler, Willscott E et al. (2014) Bipotential adult liver progenitors are derived from chronically injured mature hepatocytes. Cell Stem Cell 15:605-18
Wu, Y; Teng, B B; Brandt, M L et al. (1999) Normal perinatal rise in serum cholesterol is inhibited by hepatic delivery of adenoviral vector expressing apolipoprotein B mRNA editing enzyme (Apobec1) in rabbits. J Surg Res 85:148-57
Muzzin, P; Eisensmith, R C; Copeland, K C et al. (1997) Hepatic insulin gene expression as treatment for type 1 diabetes mellitus in rats. Mol Endocrinol 11:833-7
Kuzmin, A I; Finegold, M J; Eisensmith, R C (1997) Macrophage depletion increases the safety, efficacy and persistence of adenovirus-mediated gene transfer in vivo. Gene Ther 4:309-16
Fang, B; Wang, H; Gordon, G et al. (1996) Lack of persistence of E1- recombinant adenoviral vectors containing a temperature-sensitive E2A mutation in immunocompetent mice and hemophilia B dogs. Gene Ther 3:217-22
Brandt, M L (1996) Gene therapy in pediatric surgery. Semin Pediatr Surg 5:197-205
Bowles, N E; Eisensmith, R C; Mohuiddin, R et al. (1996) A simple and efficient method for the concentration and purification of recombinant retrovirus for increased hepatocyte transduction in vivo. Hum Gene Ther 7:1735-42
Brandt, M L; Eckert, J W; Buerkle, C J et al. (1996) The subcutaneous spleen: a new model for percutaneous access to the portal venous system. J Invest Surg 9:161-6
Eckert, J W; Buerkle, C J; Major, A M et al. (1995) In situ hybridization utilizing a Y chromosome DNA probe. Use as a cell marker for hepatocellular transplantation. Transplantation 59:109-11
Fang, B; Eisensmith, R C; Wang, H et al. (1995) Gene therapy for hemophilia B: host immunosuppression prolongs the therapeutic effect of adenovirus-mediated factor IX expression. Hum Gene Ther 6:1039-44

Showing the most recent 10 out of 25 publications